Business
Rakovina Therapeutics Announces Stock Option Grants
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Announces Stock Option Grants\n\n\n\n VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “\n \n Company\n \n ” or “\n \n Rakovina\n \n ”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its board of directors has approved the grant of an aggregate of 540,000 stock options (the “\n \n Options\n \n ”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan.\n \n\n Each Option is exercisable for up to five years at a price of $0.70 per share and shall vest in equal parts every six months over the next three years.\n \n\n\n About Rakovina Therapeutics Inc.\n \n\n\n Rakovina is a biopharmaceutical research company focused on the development of innovative cancer treatments. Their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, they can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at\n \n www.rakovinatherapeutics.com\n \n .\n \n\n\n No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.\n \n\n\n\n Notice Regarding Forward-Looking Statements\n \n\n\n\n This press release may contain “forward-looking statements” regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: the Company’s objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company’s DDR platform. Forward-looking statements are necessarily base...